116 related articles for article (PubMed ID: 10945565)
1. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study.
Masood S; Bui MM
Ann Clin Lab Sci; 2000 Jul; 30(3):259-65. PubMed ID: 10945565
[TBL] [Abstract][Full Text] [Related]
2. Expression of HER2/neu in primary and metastatic breast cancer.
Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
[TBL] [Abstract][Full Text] [Related]
3. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
4. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
5. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
6. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation.
Kim YS; Konoplev SN; Montemurro F; Hoy E; Smith TL; Rondón G; Champlin RE; Sahin AA; Ueno NT
Clin Cancer Res; 2001 Dec; 7(12):4008-12. PubMed ID: 11751494
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma.
Bozzetti C; Personeni N; Nizzoli R; Guazzi A; Flora M; Bassano C; Negri F; Martella E; Naldi N; Franciosi V; Cascinu S
Cancer; 2003 Oct; 99(5):310-5. PubMed ID: 14579298
[TBL] [Abstract][Full Text] [Related]
8. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
Stark A; Lu M; Mackowiak P; Linden M
Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
[TBL] [Abstract][Full Text] [Related]
9. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
Tanner M; Järvinen P; Isola J
Cancer Res; 2001 Jul; 61(14):5345-8. PubMed ID: 11454672
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu oncogene expression in advanced breast cancer.
Krogerus LA; Leivonen M
Cancer Detect Prev; 2001; 25(1):1-7. PubMed ID: 11270416
[TBL] [Abstract][Full Text] [Related]
11. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
13. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
Kilpatrick SE; Geisinger KR; King TS; Sciarrotta J; Ward WG; Gold SH; Bos GD
Mod Pathol; 2001 Dec; 14(12):1277-83. PubMed ID: 11743051
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.
Thomson TA; Hayes MM; Spinelli JJ; Hilland E; Sawrenko C; Phillips D; Dupuis B; Parker RL
Mod Pathol; 2001 Nov; 14(11):1079-86. PubMed ID: 11706067
[TBL] [Abstract][Full Text] [Related]
16. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas.
Regitnig P; Schippinger W; Lindbauer M; Samonigg H; Lax SF
J Pathol; 2004 Aug; 203(4):918-26. PubMed ID: 15258994
[TBL] [Abstract][Full Text] [Related]
17. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases.
Gårdmark T; Wester K; De la Torre M; Carlsson J; Malmström PU
BJU Int; 2005 May; 95(7):982-6. PubMed ID: 15839918
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer in the 21st century: neu opportunities and neu challenges.
Schnitt SJ
Mod Pathol; 2001 Mar; 14(3):213-8. PubMed ID: 11266529
[TBL] [Abstract][Full Text] [Related]
19. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
20. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
